On: Rapamycin and dogs — man’s best friends?
Date: August 2018
- Involved in dog ageing research project:
- Live in similar environment as humans.
- Die from similar diseases as humans (although cancer is the most common in dogs, versus heart disease in humans).
- Rapamycin is immunosuppressant (see mTOR write-up).
- Reduces T cell proliferation on high doses (protective in organ transplants).
- But, becomes immunoprotective on low doses / cycling.
- Likely through enhanced stem cell function.
- Rapamycin may delay ageing and also restore functionality.
- Such as heart function.
- Difficult to measure.
- Can be beneficial or detrimental.
- Rapamycin seems to activate beneficial autophagy.
- Ability of the body to detect cancer cells goes down with age as the immune function deteriorates.
- Rapamycin (in proper dosage) can enhance the body’s immune surveillance.
- Neurodegenerative diseases:
- Diseases of aging.
- Rapamycin may also be useful in halting the development of Alzheimer’s Disease.
- Likely through autophagy, stopping protein accumulation.
- Caloric restriction:
- Rapamycin and caloric restriction both inhibit mTOR.
- While there is some overlap between the tow, rapamycin likely covers a broader array of mTOR inhibition.
- Little know about interaction between rapamycin and the metabolome.
- The decrease of intestinal barrier function with age causes inflammation.
- Rapamycin may stop decrease of function and help lower chronic inflammation.